PD
OBIO icon

Point72 (DIFC)’s Orchestra BioMed OBIO Stock Holding History

Point72 (DIFC)’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$675 Sell
272
-82
-23% -$226 ﹤0.01% 1072
2025
Q2 		$949 Buy
+354
New +$1.03K ﹤0.01% 1436

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 (DIFC)'s OBIO Position: Q3 2025 in Review

Point72 (DIFC) reduced its Orchestra BioMed (OBIO) stake by 23% in Q3 2025, selling an estimated $226 and leaving 272 shares worth $675. The position accounts for ﹤0.01% of the portfolio, ranked #1072.

Point72 (DIFC) first reported a position in OBIO in Q2 2025 and has held it in 2 quarters since. The position peaked at $949 in Q2 2025. 52 funds tracked by Wall St. Rank hold OBIO as of Q3 2025.

  • Point72 (DIFC) held 272 shares of Orchestra BioMed worth $675 as of Q3 2025.
  • Point72 (DIFC) sold 82 Orchestra BioMed shares in Q3 2025, an estimated $226.
  • Orchestra BioMed made up ﹤0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #1072 holding.
  • Point72 (DIFC) first reported a position in Orchestra BioMed in Q2 2025 and has held it in 2 quarters since.
  • Point72 (DIFC)'s Orchestra BioMed position peaked at $949 in Q2 2025.
  • 52 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.